A systems biology approach for studying neurodegenerative diseases

Lam S., Bayraktar A., Zhang C., TÜRKEZ H., Nielsen J., Boren J., ...Daha Fazla

DRUG DISCOVERY TODAY, cilt.25, sa.7, ss.1146-1159, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 25 Sayı: 7
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.drudis.2020.05.010
  • Dergi Adı: DRUG DISCOVERY TODAY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, BIOSIS, Biotechnology Research Abstracts, Communication Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Metadex, Civil Engineering Abstracts
  • Sayfa Sayıları: ss.1146-1159
  • Atatürk Üniversitesi Adresli: Evet

Özet

Neurodegenerative diseases (NDDs), such as Alzheimer's (AD) and Parkinson's (PD), are among the leading causes of lost years of healthy life and exert a great strain on public healthcare systems. Despite being first described more than a century ago, no effective cure exists for AD or PD. Although extensively characterised at the molecular level, traditional neurodegeneration research remains marred by narrow-sense approaches surrounding amyloid beta (A beta), tau, and alpha-synuclein (alpha-syn). A systems biology approach enables the integration of multi-omics data and informs discovery of biomarkers, drug targets, and treatment strategies. Here, we present a comprehensive timeline of high-throughput data collection, and associated biotechnological advancements and computational analysis related to AD and PD. We hereby propose that a philosophical change in the definitions of AD and PD is now needed.